Other · developed by Sanofi
Riliprubart (SAR445088, BIVV-020) is a drug given as an intravenous or subcutaneous solution.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06290141 | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy | Recruiting | SNY |
| NCT04658472 | Phase 2 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Completed | SNY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Chronic Inflammatory Demyelinating PolyneuropathyChronic Inflammatory Demyelinating Polyradiculoneuropathy
Updated Nov 22, 2026. Something wrong or missing? Report it on the SNY page.
See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SNY catalysts and pipeline →